1 |
Owens DG. Adverse effects of antipsychotic agents. Do newer agents offer advantages? Drugs 1996;51:895-930.
DOI
ScienceOn
|
2 |
Conley RR. Optimizing treatment with clozapine. J Clin Psychiatry 1998;59 Suppl 3:44-48.
|
3 |
McElroy SL, Dessain EC, Pope HG Jr, Cole JO, Keck PE Jr, Frankenberg FR, et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 1991;52:411-414.
|
4 |
Suppes T, McElroy SL, Gilbert J, Dessain EC, Cole JO. Clozapine in the treatment of dysphoric mania. Biol Psychiatry 1992;32:270-280.
DOI
ScienceOn
|
5 |
Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995;152:183-190.
DOI
|
6 |
Volavka J, Zito JM, Vitrai J, Czobar P. Clozapine effects on hostility and aggression in schizophrenia. J Clin Psychopharmacol 1993;13: 287-289.
|
7 |
Krakowski MI, Czobor P, Citrome L, Bark N, Cooper TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2006;63:622-629.
DOI
ScienceOn
|
8 |
Weintraub D, Hurtig HI. Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies. Am J Psychiatry 2007;164:1491-1498.
DOI
ScienceOn
|
9 |
Baldessarini RJ, Frankenburg FR. Clozapine. A novel antipsychotic agent. N Engl J Med 1991;324:746-754.
DOI
ScienceOn
|
10 |
Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993;329:162-167.
DOI
ScienceOn
|
11 |
Roh S, Ahn DH, Kim YS, Lee BH. Dilated cardiomyopathy associated with clozapine. J Korean Neuropsychiatr Assoc 2005;44:125-128.
|
12 |
Young CR, Bowers MB Jr, Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull 1998;24:381-390.
DOI
ScienceOn
|
13 |
La Grenade L, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med 2001;345:224-225.
DOI
ScienceOn
|
14 |
Mackin P. Cardiac side effects of psychiatric drugs. Hum Psychopharmacol 2008;23 Suppl 1:3-14.
DOI
|
15 |
Hagg S, Spigset O, Bate A, Soderstrom TG. Myocarditis related to clozapine treatment. J Clin Psychopharmacol 2001;21:382-388.
DOI
ScienceOn
|
16 |
Kilian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999;354:1841-1845.
DOI
ScienceOn
|
17 |
Commitee on safety of medicines. Myocarditis with antipsychotics: recent cases with clozapine (clozaril). Current Problems in Pharmacovigiliance 1993;19:9-10.
|
18 |
Coulter DM, Bate A, Meyboom RH, Lindquist M, Edwards IR. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ 2001;322:1207-1209.
DOI
ScienceOn
|
19 |
Novartis. Dear health care provider: myocarditis added to boxed warning;2002.
|
20 |
Haas SJ, Hill R, Krum H, Liew D, Tonkin A, Demos L, et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 2007;30:47-57.
DOI
ScienceOn
|
21 |
Calabrese F, Thiene G. Myocarditis and inflammatory cardiomyopathy: microbiological and molecular biological aspects. Cardiovasc Res 2003;60:11-25.
DOI
ScienceOn
|
22 |
Ruetsch O, Viala A, Bardou H, Martin P, Vacheron MN. [Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management]. Encephale 2005;31(4 Pt 1):507-516.
DOI
ScienceOn
|
23 |
Kim Y, Ahn Y, Jeong S, Shin Y. Clinical use of clozapine: 89 questions and answers. Seoul: Seoul National University Press;2009. p.167-169.
|
24 |
Razminia M, Salem Y, Devaki S, Shah N, Khosla S. Clozapine induced myopericarditis: early recognition improves clinical outcome. Am J Ther 2006;13:274-276.
DOI
ScienceOn
|
25 |
Feldman AM, McNamara D. Myocarditis. N Engl J Med 2000;343:1388-1398.
DOI
ScienceOn
|
26 |
Tham JC, Dickson RA. Clozapine-induced fevers and 1-year clozapine discontinuation rate. J Clin Psychiatry 2002;63:880-884.
DOI
ScienceOn
|
27 |
Pollmacher T, Schuld A, Kraus T, Haack M, Hinze-Selch D. [On the clinical relevance of clozapine-triggered release of cytokines and soluble cytokine-receptors]. Fortschr Neurol Psychiatr 2001;69 Suppl 2:S65-S74.
DOI
|
28 |
Burian J, Buser P, Eriksson U. Myocarditis: the immunologist's view on pathogenesis and treatment. Swiss Med Wkly 2005;135:359-364.
|
29 |
Vaddadi KS, Soosai E, Vaddadi G. Low blood selenium concentrations in schizophrenic patients on clozapine. Br J Clin Pharmacol 2003;55:307-309.
DOI
ScienceOn
|
30 |
Hill GR, Harrison-Woolrych M. Clozapine and myocarditis: a case series from the New Zealand Intensive Medicines Monitoring Programme. N Z Med J 2008;121:68-75.
|
31 |
Dukes MN. The importance of adverse reactions in drug regulation. Drug Saf 1990;5:3-6.
DOI
ScienceOn
|
32 |
Wooltorton E. Antipsychotic clozapine (Clozaril): myocarditis and cardiovascular toxicity. CMAJ 2002;166:1185-1186.
|
33 |
Degner D, Bleich S, Grohmann R, Bandelow B, Ruther E. Myocarditis associated with clozapine treatment. Aust N Z J Psychiatry 2000;34:880.
DOI
ScienceOn
|